Indaptus Therapeutics

Contributing Author

Recent Articles by Indaptus Therapeutics

Jun-02	Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab INDP GlobeNewswire
May-14	Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update INDP GlobeNewswire
May-08	Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit INDP GlobeNewswire